Trulicity vs Mounjaro: Weight Loss & Differences

Trulicity vs glp-1/mounjaro-vs-wegovy">Mounjaro comes down to one big difference: Trulicity (dulaglutide) is a single GLP-1 receptor agonist, while Mounjaro (tirzepatide) is a dual GLP-1/GIP agonist made by the same company, Eli Lilly. Both are once-weekly injections FDA-approved for type 2 diabetes, but tirzepatide is substantially more powerful for both blood sugar and weight loss. Neither drug is FDA-approved for weight loss on its own.

If you take one of these medicines, or your clinician has mentioned switching, you may want to understand how they actually differ. This guide breaks down the two drugs side by side, what the trials show, and why so many people move from one to the other. This article is informational only and is not medical advice.

The core difference in Trulicity vs Mounjaro

Both drugs are made by Eli Lilly and both are given as a once-weekly injection, so on the surface they look similar. The key difference is the mechanism. Trulicity contains dulaglutide, which activates a single hormone pathway, the GLP-1 receptor. Mounjaro contains tirzepatide, which activates two pathways at once: GLP-1 and GIP. This dual action is why tirzepatide is described as a "twincretin," and it helps explain why Mounjaro tends to produce stronger results. You can read more about the mechanism in our guide to how tirzepatide works.

Both medicines lower blood sugar, slow how fast the stomach empties, and reduce appetite. The GIP component in tirzepatide appears to add extra benefit for both glucose control and body weight, which is the practical reason Mounjaro often outperforms older GLP-1 drugs like Trulicity. In simple terms, Trulicity pulls one lever while Mounjaro pulls two, and that second lever is what tends to translate into greater effects in real-world use.

It is worth stressing that "stronger" does not automatically mean "better for you." The right drug depends on your blood sugar targets, your weight goals, how well you tolerate side effects, cost and insurance coverage, and your overall medical history. That is exactly why the comparison below is meant to inform a conversation with a clinician rather than replace it.

Trulicity vs Mounjaro at a glance

Feature	Trulicity	Mounjaro
Active ingredient	Dulaglutide	Tirzepatide
Drug class	GLP-1 receptor agonist	Dual GLP-1/GIP agonist
Dosing frequency	Once weekly injection	Once weekly injection
Doses	0.75, 1.5, 3, 4.5 mg	2.5 mg starter, then 5 up to 15 mg
FDA-approved use	Type 2 diabetes	Type 2 diabetes
Weight loss	Modest (a few pounds)	Substantial (up to about 20.9% in obesity trials)
A1c reduction	Meaningful	Greater than Trulicity

Dosing and devices

Trulicity comes in four once-weekly doses: 0.75, 1.5, 3, and 4.5 mg. It is well known for its auto-injector, which has a hidden needle so you never see or handle it. Many people find this device especially easy to use, which is a genuine advantage for anyone nervous about injections.

Mounjaro starts at a 2.5 mg once-weekly dose for the first month. That starter dose is meant to reduce side effects, not to treat, and it is stepped up to 5 mg and higher over time, up to a maximum of 15 mg once weekly. Because the dose is increased gradually, a clinician always sets and adjusts the schedule.

Effectiveness: what the trials show

Tirzepatide (Mounjaro) is substantially more powerful than dulaglutide (Trulicity) for both A1c and weight. In Lilly's SURPASS program, the large set of trials that tested tirzepatide in type 2 diabetes, tirzepatide outperformed other GLP-1 drugs on blood sugar control and weight. For weight specifically, tirzepatide reached about 20.9% average body weight reduction at the highest dose in obesity trials, a level that dulaglutide does not approach.

Dulaglutide, by contrast, produces modest weight loss, often only a few pounds, even though it is effective for blood sugar. That gap is the single biggest reason many people switch from Trulicity to Mounjaro when they need better glucose control or more weight loss. To compare all the major options side by side, see our overviews of GLP-1 weight loss results by drug and the best GLP-1 for weight loss.

Keep in mind that trial averages are not promises. The roughly 20.9% figure for tirzepatide comes from obesity trials at the highest dose, and individual results vary widely depending on dose, diet, activity, and how a person responds. Some people on Trulicity do lose a meaningful amount, and some people on Mounjaro lose less than the headline numbers. The point of comparing the averages is to understand the general direction, not to predict any one person's outcome.

An important note on weight loss approval

Neither Trulicity nor Mounjaro is FDA-approved for weight loss. Tirzepatide's weight-approved twin is Zepbound, which is the same molecule as Mounjaro but marketed and approved specifically for chronic weight management. Dulaglutide has no weight-approved version at all. So for weight specifically, the on-label tirzepatide option is Zepbound, not Mounjaro. Our comparison of Mounjaro vs Zepbound explains how those two relate, and you can check the full list of FDA-approved GLP-1 medications to see which drug is cleared for which use.

Side effects and safety

Both drugs share the GLP-1 class side effect profile. The most common issues are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These tend to be concentrated early in treatment and during dose increases, then often ease as the body adjusts. This is one reason Mounjaro is titrated slowly from its 2.5 mg starter dose. For more detail, see our guide to Mounjaro side effects.

Both medicines carry a boxed warning about thyroid C-cell tumors, based on animal studies, and both should be avoided by people with a personal or family history of medullary thyroid cancer or MEN 2. The risk of low blood sugar is generally low on its own but rises when either drug is combined with insulin or a sulfonylurea, so those combinations may need dose adjustments from a clinician.

Switching from Trulicity to Mounjaro

Because Mounjaro is generally stronger, moving from Trulicity to Mounjaro is a common step for people who need better control. Any switch is a decision made with a clinician, who chooses the right starting dose for Mounjaro rather than matching your old Trulicity dose. Mounjaro almost always begins at its 2.5 mg starter dose regardless of what Trulicity dose you were on, so a clinician manages the transition and the titration schedule. Do not change or combine these medicines on your own.

How they compare to other options

These two drugs are part of a crowded field. If you are weighing other combinations, our related guides may help: Trulicity vs Ozempic compares dulaglutide against semaglutide, while Ozempic vs Mounjaro pits semaglutide against tirzepatide directly. Together these give a fuller picture of where Trulicity and Mounjaro sit among the once-weekly injectables.

Bottom line on Trulicity vs Mounjaro

For both blood sugar and weight, Mounjaro (tirzepatide) is generally the stronger of the two. Trulicity may still suit people who prefer its simpler, hidden-needle device or who tolerate it better. And for weight specifically, remember that the on-label tirzepatide option is Zepbound rather than Mounjaro. Whichever direction fits your situation, the choice, the prescription, and any switch are decisions for a clinician who knows your full medical history.